Results 111 to 120 of about 43,468 (306)

Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism [PDF]

open access: bronze, 2010
Ernst ter Haar   +8 more
openalex   +1 more source

The Calcitonin/Calcitonin Gene-Related Peptide Family in Invertebrate Deuterostomes

open access: yesFrontiers in Endocrinology, 2018
Calcitonin (CT)/CT gene-related peptide (CGRP) family peptides (CT/CGRP family peptides) including CT, CGRP, adrenomedullin, amylin, and CT receptor-stimulating peptide have been identified from various vertebrates and perform a variety of important ...
Toshio Sekiguchi
doaj   +1 more source

Dynamics of the CD9 interactome during bacterial infection of epithelial cells by proximity labelling proteomics

open access: yesThe FEBS Journal, EarlyView.
We describe the CD9 interactome in epithelial cells for the first time. The interactome is diverse and dynamic and changes dependent on infection with specific bacteria. We validate these data by showing functional interaction between CD9 with CD44 or CD147. We therefore demonstrate that CD9 is a universal organiser of bacterial adhesion platforms able
Paige A. Wolverson   +5 more
wiley   +1 more source

Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine

open access: yesDrug Design, Development and Therapy
Mengyi Li, Siyong Huang, Jiabao Li, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Li M, Huang S, Li J, Hu X, Chen J
doaj  

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow   +3 more
wiley   +1 more source

POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting [PDF]

open access: bronze, 2022
Martin Drießen   +10 more
openalex   +1 more source

Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen   +6 more
wiley   +1 more source

The potential role of sleep quality in the relationship between glymphatic function and migraine frequency: Insights from a cross‐sectional study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to explore the association between glymphatic function, as assessed by the diffusion tensor imaging along perivascular space (DTI‐ALPS) index, and headache frequency in individuals with migraine. Additionally, it evaluated whether sleep quality modulates this relationship.
Raffaele Ornello   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy